Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Reata Pharmaceuticals stock in Canada | $136.74

Own Reata Pharmaceuticals shares in just a few minutes.

Reata Pharmaceuticals, Inc
+$1.12 (+0.87%)

Reata Pharmaceuticals is a biotechnology business based in the US. Reata Pharmaceuticals stocks (RETA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $139.36 – an increase of 7.32% over the previous week. Reata Pharmaceuticals employs 261 staff and has a trailing 12-month revenue of around $8.6 million.

How to buy Reata Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: RETA in this case.
  5. Research Reata Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your Reata Pharmaceuticals stocks. It's that simple.

How has Coronavirus impacted Reata Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Reata Pharmaceuticals's stock price has had significant negative movement.

Its last market close was $136.74, which is 35.24% down on its pre-crash value of $211.14 and 21.00% up on the lowest point reached during the March crash when the stocks fell as low as $113.01.

If you had bought $1,000 worth of Reata Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $536.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $567.47.

Reata Pharmaceuticals stock price

Use our graph to track the performance of RETA stocks over time.

Reata Pharmaceuticals stocks at a glance

Information last updated 2021-07-22.
Latest market close$136.74
52-week range$76.34 - $186.817
50-day moving average $139.1821
200-day moving average $116.7071
Wall St. target price$237
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.056

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Reata Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Reata Pharmaceuticals price performance over time

Historical closes compared with the last close of $136.74

1 month (2021-06-25) -8.81%
3 months (2021-04-26) 36.64%

Reata Pharmaceuticals financials

Revenue TTM USD$8.6 million
Gross profit TTM USD$-150,061,000
Return on assets TTM -18.07%
Return on equity TTM -89.06%
Profit margin 0%
Book value $10.183
Market capitalisation USD$4.7 billion

TTM: trailing 12 months

How to short and sell Reata Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "RETA.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.8 million Reata Pharmaceuticals stocks held short by investors – that's known as Reata Pharmaceuticals's "short interest". This figure is 9.6% up from 3.5 million last month.

There are a few different ways that this level of interest in shorting Reata Pharmaceuticals stocks can be evaluated.

Reata Pharmaceuticals's "short interest ratio" (SIR)

Reata Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Reata Pharmaceuticals stocks currently shorted divided by the average quantity of Reata Pharmaceuticals stocks traded daily (recently around 486172.58883249). Reata Pharmaceuticals's SIR currently stands at 7.88. In other words for every 100,000 Reata Pharmaceuticals stocks traded daily on the market, roughly 7880 stocks are currently held short.

However Reata Pharmaceuticals's short interest can also be evaluated against the total number of Reata Pharmaceuticals stocks, or, against the total number of tradable Reata Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Reata Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding stocks (for every 100,000 Reata Pharmaceuticals stocks in existence, roughly 110 stocks are currently held short) or 0.1277% of the tradable stocks (for every 100,000 tradable Reata Pharmaceuticals stocks, roughly 128 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Reata Pharmaceuticals.

Find out more about how you can short Reata Pharmaceuticals stock.

Reata Pharmaceuticals stock dividends

We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Reata Pharmaceuticals stock price volatility

Over the last 12 months, Reata Pharmaceuticals's stocks have ranged in value from as little as $76.34 up to $186.817. A popular way to gauge a stock's volatility is its "beta".

RETA.US volatility(beta: 1.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.5169. This would suggest that Reata Pharmaceuticals's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Reata Pharmaceuticals overview

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site